Press Release

MARF admits a new 30-million-euro Commercial Paper Programme from Eurofirms

27 December, 2022

BME's fixed income market, MARF, has admitted to trading today a new 30-million-euro Commercial Paper (CP) Programme from Eurofirms Group. This programme is the first registered by the company on the MARF and will allow it to access qualified investors to diversify its short-term sources of financing. The CPs to be issued under the programme will have maturities ranging from three days to a maximum of two years and will have unit notional amounts of 100,000 euro.

Banco de Sabadell y PKF Attest Capital Markets are participating as Collaborating Entities. PKF Attest is also the Registered Advisor of Eurofirms in the MARF. Banco Inversis will act as Paying Agent of the issues.

J&A Garrigues has provided legal advice to the new issuer in the registration of the Programme.

Eurofirms has a BB credit rating, stable perspective, from EthiFinance Ratings.

Eurofirms Group is the first national capital company specialized in the integrated talent management through a range of services that includes temporary employment services (ETT), tailor-made in-plant services, outsourcing, headhunting, services externalization, talent management (outplacement, strategic talent consultancy,  training and solutions adapted to the employee), etc. For the development of these activities the Group has an online employment portal -Cornerjob- and various technological solutions of its own development that allow the digital management of the relationship with candidates, workers and clients.

For 15 years the Group has been committed to social commitment through its Foundation, whose objective is to promote the labor integration of people with disabilities.  

During its more than 30 years of activity since its incorporation in 1991 Eurofirms has expanded its geographical scope and currently operates internationally through 150 delegations in Spain, Portugal,  Chile, Italy and France.

At the end of 2021 the company reported a turnover of 487.2 million euros and an EBITDA of 6.2 million euros.

Copyright® BME 2024
[ ]